Xiaojia Wang

机构：Zhejiang Cancer Hospital, First Affiliated Hospital of Henan University of Science and Technology

发表论文 90 篇 · 总被引 1943 次 · h-index 21

代表论文

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 (2024 · Journal of Clinical Oncology · 被引 163)
• Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial (2023 · BMJ · 被引 87)
• ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
• Global, reginal, national burden and risk factors in female breast cancer from 1990 to 2021 (2024 · iScience · 被引 20)
• Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial (2024 · Journal of Translational Internal Medicine · 被引 18)
• Radiomic Models Predict Tumor Microenvironment Using Artificial Intelligence—the Novel Biomarkers in Breast Cancer Immune Microenvironment (2023 · Technology in Cancer Research & Treatment · 被引 14)